Regeneron to Initiate COVID-19 Antibody Program in Early Summer

 Regeneron to Initiate COVID-19 Antibody Program in Early Summer

Shots:

  • Regeneron advances its program to discover and develop a novel multi-Ab cocktail, administered as prophylaxis before exposure to the SARS-CoV-2 virus or as a treatment for already infected patients
  • The company plans to initiate the clinical studies by early summer and has isolated mAb from its VelocImmune mice and from humans who have recovered from COVID-19 and would pick two of them to test as a cocktail treatment
  • The program follows Regeneron’s ongoing clinical program evaluating Kevzara (sarilumab, an IL-6 receptor antibody) in severe COVID-19 patients

Click here ­to­ read full press release/ article | Ref: Regeneron  | Image:  Regeneron

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post